Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.


Journal article


Jesko Momotow, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Sven Borchmann, Bastian v. Tresckow, Carsten Kobe, Andreas Engert, Stephanie Sasse
HemaSphere, vol. 3(5), 2019 Aug 27

Cite

APA
Momotow, J., Goergen, H., Behringer, K., Bröckelmann, P. J., Borchmann, S., v. Tresckow, B., … Sasse, S. (2019). Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center. HemaSphere, 3(5).

Chicago/Turabian
Momotow, Jesko, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Sven Borchmann, Bastian v. Tresckow, Carsten Kobe, Andreas Engert, and Stephanie Sasse. “Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.” HemaSphere 3, no. 5 (August 27, 2019).

MLA
Momotow, Jesko, et al. “Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.” HemaSphere, vol. 3, no. 5, Aug. 2019.